Edumed s.r.o. — Clinical Trial Site

53 Registered trials

25 Currently recruiting

Organisation

Edumed s.r.o.

Location

Nachod, Czechia

Identifier

ORG-100044341

Address

Smetanova 91, 550 01, Czechia

Departments

#3167:Kardiologie
1104: Kardiologicka ambulance
1107: Kardiologie
1906: Kardiologicka ambulance
2315: Kardiologie
3167: Kardiologie
4206: Plicni ambulance
7519
cardiology
diabetogie - private
Diabetologická ambulance
Edumed s.r.o. , Náchod - Kardilologická ambulance
Edumed s.r.o. Broumov - Kardilologická ambulance
Kardiologicka ambulace
Kardiologická ambulance
Kardiologická ambulance Broumov
Kardiologická ambulance Hradec Králové
Kardiologická ambulance Jaroměř
Kardiologicka, diabetologicka a interni ambulance
Kardiologie
Kardiologie a vnitřní lékařství
N/A
NA
Private Practice

Clinical trials at this site (53)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
A Study to Evaluate the Effect of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) or Obicetrapib on LDL-C in Participants With Type 2… Recruiting

2025-521936-12-00 Adults with Type 2 Diabetes and/or Metabolic Syndrome 5 2026-04-24
CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur… Recruiting

2024-518899-31-00 Variant or wild-type transthyretin (TTR) amyloid cardio 5 2025-12-19
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Graves’ Disease 4 2025-11-21
A Phase 2 Study of the Effects and Safety of PF-07328948 in Adults with Heart Failure (BRANCH-HF) Recruiting

2024-518438-94-00 Heart failure 4 2025-10-24
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on… Recruiting

2022-502135-19-00 Calcific Aortic Valve Stenosis 4 2024-07-18
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit… Recruiting

2023-504835-42-00 Heart Failure (Heart Failure with Reduced Ejection Frac 4 2024-02-29
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Severe hypertriglyceridemia (SHTG) 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03